Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Reactive oxygen species (ROS) generation is stimulated by κ opioid receptor activation through phosphorylated c-Jun N-terminal kinase and inhibited by p38 mitogen-activated protein kinase (MAPK) activation.

Schattauer SS, Bedini A, Summers F, Reilly-Treat A, Andrews MM, Land BB, Chavkin C.

J Biol Chem. 2019 Nov 8;294(45):16884-16896. doi: 10.1074/jbc.RA119.009592. Epub 2019 Oct 1.

PMID:
31575661
2.

Repeated Administration of Norbinaltorphimine Produces Cumulative Kappa Opioid Receptor Inactivation.

Chavkin C, Cohen JH, Land BB.

Front Pharmacol. 2019 Feb 6;10:88. doi: 10.3389/fphar.2019.00088. eCollection 2019.

3.

Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.

Abraham AD, Schattauer SS, Reichard KL, Cohen JH, Fontaine HM, Song AJ, Johnson SD, Land BB, Chavkin C.

J Neurosci. 2018 Sep 12;38(37):8031-8043. doi: 10.1523/JNEUROSCI.0653-18.2018. Epub 2018 Aug 3.

4.

Kappa-opioid antagonists as stress resilience medications for the treatment of alcohol use disorders.

Chavkin C.

Neuropsychopharmacology. 2018 Aug;43(9):1803-1804. doi: 10.1038/s41386-018-0046-4. Epub 2018 Mar 27. No abstract available.

5.

Peroxiredoxin 6 mediates Gαi protein-coupled receptor inactivation by cJun kinase.

Schattauer SS, Land BB, Reichard KL, Abraham AD, Burgeno LM, Kuhar JR, Phillips PEM, Ong SE, Chavkin C.

Nat Commun. 2017 Sep 29;8(1):743. doi: 10.1038/s41467-017-00791-2.

6.

κ-Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition.

Abraham AD, Fontaine HM, Song AJ, Andrews MM, Baird MA, Kieffer BL, Land BB, Chavkin C.

Neuropsychopharmacology. 2018 Jan;43(2):362-372. doi: 10.1038/npp.2017.133. Epub 2017 Jun 26.

7.

Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.

Schattauer SS, Kuhar JR, Song A, Chavkin C.

Cell Signal. 2017 Apr;32:59-65. doi: 10.1016/j.cellsig.2017.01.016. Epub 2017 Jan 11.

8.

Dynorphin, Dysphoria, and Dependence: the Stress of Addiction.

Chavkin C, Koob GF.

Neuropsychopharmacology. 2016 Jan;41(1):373-4. doi: 10.1038/npp.2015.258. Review. No abstract available.

9.

Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons.

Ehrich JM, Messinger DI, Knakal CR, Kuhar JR, Schattauer SS, Bruchas MR, Zweifel LS, Kieffer BL, Phillips PE, Chavkin C.

J Neurosci. 2015 Sep 16;35(37):12917-31. doi: 10.1523/JNEUROSCI.2444-15.2015.

10.

Kappa Antagonist JDTic in Phase 1 Clinical Trial.

Chavkin C, Martinez D.

Neuropsychopharmacology. 2015 Aug;40(9):2057-8. doi: 10.1038/npp.2015.74. No abstract available.

11.

Mu opioid receptor stimulation activates c-Jun N-terminal kinase 2 by distinct arrestin-dependent and independent mechanisms.

Kuhar JR, Bedini A, Melief EJ, Chiu YC, Striegel HN, Chavkin C.

Cell Signal. 2015 Sep;27(9):1799-806. doi: 10.1016/j.cellsig.2015.05.019. Epub 2015 Jun 5.

12.

Role of G Protein-Coupled Receptor Kinases 2 and 3 in μ-Opioid Receptor Desensitization and Internalization.

Lowe JD, Sanderson HS, Cooke AE, Ostovar M, Tsisanova E, Withey SL, Chavkin C, Husbands SM, Kelly E, Henderson G, Bailey CP.

Mol Pharmacol. 2015 Aug;88(2):347-56. doi: 10.1124/mol.115.098293. Epub 2015 May 26.

13.

κ Agonists as a novel therapy for menopausal hot flashes.

Oakley AE, Steiner RA, Chavkin C, Clifton DK, Ferrara LK, Reed SD.

Menopause. 2015 Dec;22(12):1328-34. doi: 10.1097/GME.0000000000000476.

14.

How does stress-induced activation of the kappa opioid system increase addiction risk?

Chavkin C, Ehrich JM.

Biol Psychiatry. 2014 Nov 15;76(10):760-2. doi: 10.1016/j.biopsych.2014.08.015. Epub 2014 Oct 31. No abstract available.

15.

Kappa opioid receptor activation potentiates the cocaine-induced increase in evoked dopamine release recorded in vivo in the mouse nucleus accumbens.

Ehrich JM, Phillips PE, Chavkin C.

Neuropsychopharmacology. 2014 Dec;39(13):3036-48. doi: 10.1038/npp.2014.157. Epub 2014 Jun 27.

16.

Repeated stress exposure causes strain-dependent shifts in the behavioral economics of cocaine in rats.

Groblewski PA, Zietz C, Willuhn I, Phillips PE, Chavkin C.

Addict Biol. 2015 Mar;20(2):297-301. doi: 10.1111/adb.12123. Epub 2014 Feb 15.

17.

Characterization of individual mouse cerebrospinal fluid proteomes.

Smith JS, Angel TE, Chavkin C, Orton DJ, Moore RJ, Smith RD.

Proteomics. 2014 May;14(9):1102-6. doi: 10.1002/pmic.201300241. Epub 2014 Mar 20.

18.

Arrestin-mediated activation of p38 MAPK: molecular mechanisms and behavioral consequences.

Chavkin C, Schattauer SS, Levin JR.

Handb Exp Pharmacol. 2014;219:281-92. doi: 10.1007/978-3-642-41199-1_14.

PMID:
24292835
19.

Disruption of dopamine neuron activity pattern regulation through selective expression of a human KCNN3 mutation.

Soden ME, Jones GL, Sanford CA, Chung AS, Güler AD, Chavkin C, Luján R, Zweifel LS.

Neuron. 2013 Nov 20;80(4):997-1009. doi: 10.1016/j.neuron.2013.07.044. Epub 2013 Oct 24.

20.

Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ.

Pharmacol Rev. 2013 Jan 15;65(1):223-54. doi: 10.1124/pr.112.005942. Print 2013 Jan. Review.

21.

Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake.

Schindler AG, Messinger DI, Smith JS, Shankar H, Gustin RM, Schattauer SS, Lemos JC, Chavkin NW, Hagan CE, Neumaier JF, Chavkin C.

J Neurosci. 2012 Dec 5;32(49):17582-96. doi: 10.1523/JNEUROSCI.3220-12.2012.

22.

Dynorphin--still an extraordinarily potent opioid peptide.

Chavkin C.

Mol Pharmacol. 2013 Apr;83(4):729-36. doi: 10.1124/mol.112.083337. Epub 2012 Nov 14. Review.

23.

Ligand directed signaling differences between rodent and human κ-opioid receptors.

Schattauer SS, Miyatake M, Shankar H, Zietz C, Levin JR, Liu-Chen LY, Gurevich VV, Rieder MJ, Chavkin C.

J Biol Chem. 2012 Dec 7;287(50):41595-607. doi: 10.1074/jbc.M112.381368. Epub 2012 Oct 19.

24.

Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive.

Lemos JC, Wanat MJ, Smith JS, Reyes BA, Hollon NG, Van Bockstaele EJ, Chavkin C, Phillips PE.

Nature. 2012 Oct 18;490(7420):402-6. doi: 10.1038/nature11436. Epub 2012 Sep 19.

25.

Repeated stress dysregulates κ-opioid receptor signaling in the dorsal raphe through a p38α MAPK-dependent mechanism.

Lemos JC, Roth CA, Messinger DI, Gill HK, Phillips PE, Chavkin C.

J Neurosci. 2012 Sep 5;32(36):12325-36. doi: 10.1523/JNEUROSCI.2053-12.2012.

26.

Stress-induced activation of the dynorphin/κ-opioid receptor system in the amygdala potentiates nicotine conditioned place preference.

Smith JS, Schindler AG, Martinelli E, Gustin RM, Bruchas MR, Chavkin C.

J Neurosci. 2012 Jan 25;32(4):1488-95. doi: 10.1523/JNEUROSCI.2980-11.2012.

27.

Long-term effects of neonatal stress on adult conditioned place preference (CPP) and hippocampal neurogenesis.

Hays SL, McPherson RJ, Juul SE, Wallace G, Schindler AG, Chavkin C, Gleason CA.

Behav Brain Res. 2012 Feb 1;227(1):7-11. doi: 10.1016/j.bbr.2011.10.033. Epub 2011 Oct 28.

28.

Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction.

Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB, Lemos JC, Hagan CE, Neumaier JF, Quintana A, Palmiter RD, Chavkin C.

Neuron. 2011 Aug 11;71(3):498-511. doi: 10.1016/j.neuron.2011.06.011.

29.

Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.

Melief EJ, Miyatake M, Carroll FI, Béguin C, Carlezon WA Jr, Cohen BM, Grimwood S, Mitch CH, Rorick-Kehn L, Chavkin C.

Mol Pharmacol. 2011 Nov;80(5):920-9. doi: 10.1124/mol.111.074195. Epub 2011 Aug 10.

30.
31.

The therapeutic potential of κ-opioids for treatment of pain and addiction.

Chavkin C.

Neuropsychopharmacology. 2011 Jan;36(1):369-70. doi: 10.1038/npp.2010.137. No abstract available.

32.

Alpha-dystrobrevin-1 recruits alpha-catulin to the alpha1D-adrenergic receptor/dystrophin-associated protein complex signalosome.

Lyssand JS, Whiting JL, Lee KS, Kastl R, Wacker JL, Bruchas MR, Miyatake M, Langeberg LK, Chavkin C, Scott JD, Gardner RG, Adams ME, Hague C.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21854-9. doi: 10.1073/pnas.1010819107. Epub 2010 Nov 29.

33.

Agonist-induced internalization of κ-opioid receptors in noradrenergic neurons of the rat locus coeruleus.

Reyes BA, Chavkin C, Van Bockstaele EJ.

J Chem Neuroanat. 2010 Dec;40(4):301-9. doi: 10.1016/j.jchemneu.2010.09.003. Epub 2010 Sep 25.

34.

Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling.

Melief EJ, Miyatake M, Bruchas MR, Chavkin C.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11608-13. doi: 10.1073/pnas.1000751107. Epub 2010 Jun 3.

36.

Kinase cascades and ligand-directed signaling at the kappa opioid receptor.

Bruchas MR, Chavkin C.

Psychopharmacology (Berl). 2010 Jun;210(2):137-47. doi: 10.1007/s00213-010-1806-y. Epub 2010 Apr 17. Review.

37.

Trigeminal injury causes kappa opioid-dependent allodynic, glial and immune cell responses in mice.

Aita M, Byers MR, Chavkin C, Xu M.

Mol Pain. 2010 Jan 29;6:8. doi: 10.1186/1744-8069-6-8.

38.

CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior.

Bruchas MR, Land BB, Lemos JC, Chavkin C.

PLoS One. 2009 Dec 31;4(12):e8528. doi: 10.1371/journal.pone.0008528.

39.

Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.

Clayton CC, Bruchas MR, Lee ML, Chavkin C.

Mol Pharmacol. 2010 Mar;77(3):339-47. doi: 10.1124/mol.109.060558. Epub 2009 Dec 3.

40.

Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.

Land BB, Bruchas MR, Schattauer S, Giardino WJ, Aita M, Messinger D, Hnasko TS, Palmiter RD, Chavkin C.

Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19168-73. doi: 10.1073/pnas.0910705106. Epub 2009 Oct 28.

41.

Regulation of gonadotropin-releasing hormone secretion by kisspeptin/dynorphin/neurokinin B neurons in the arcuate nucleus of the mouse.

Navarro VM, Gottsch ML, Chavkin C, Okamura H, Clifton DK, Steiner RA.

J Neurosci. 2009 Sep 23;29(38):11859-66. doi: 10.1523/JNEUROSCI.1569-09.2009.

42.

Tyrosine phosphorylation of Kir3 following kappa-opioid receptor activation of p38 MAPK causes heterologous desensitization.

Clayton CC, Xu M, Chavkin C.

J Biol Chem. 2009 Nov 13;284(46):31872-81. doi: 10.1074/jbc.M109.053793. Epub 2009 Sep 22.

43.

The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Bruchas MR, Land BB, Chavkin C.

Brain Res. 2010 Feb 16;1314:44-55. doi: 10.1016/j.brainres.2009.08.062. Epub 2009 Aug 28. Review.

44.

Effects of neonatal stress and morphine on kappa opioid receptor signaling.

Vien TN, Gleason CA, Hays SL, McPherson RJ, Chavkin C, Juul SE.

Neonatology. 2009;96(4):235-43. doi: 10.1159/000220763. Epub 2009 May 27.

45.

Differential noxious and motor tolerance of chronic delta opioid receptor agonists in rodents.

Beaudry H, Proteau-Gagné A, Li S, Dory Y, Chavkin C, Gendron L.

Neuroscience. 2009 Jun 30;161(2):381-91. doi: 10.1016/j.neuroscience.2009.03.053. Epub 2009 Mar 27.

46.

Effects of acute agonist treatment on subcellular distribution of kappa opioid receptor in rat spinal cord.

Wang Y, Xu W, Huang P, Chavkin C, Van Bockstaele EJ, Liu-Chen LY.

J Neurosci Res. 2009 May 15;87(7):1695-702. doi: 10.1002/jnr.21971.

47.

Subcellular targeting of kappa-opioid receptors in the rat nucleus locus coeruleus.

Reyes BA, Chavkin C, van Bockstaele EJ.

J Comp Neurol. 2009 Jan 20;512(3):419-31. doi: 10.1002/cne.21880.

48.

Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2.

Bruchas MR, Xu M, Chavkin C.

Neuroreport. 2008 Sep 17;19(14):1417-22. doi: 10.1097/WNR.0b013e32830dd655.

49.

Partial infraorbital nerve ligation as a model of trigeminal nerve injury in the mouse: behavioral, neural, and glial reactions.

Xu M, Aita M, Chavkin C.

J Pain. 2008 Nov;9(11):1036-48. doi: 10.1016/j.jpain.2008.06.006. Epub 2008 Aug 16.

50.

Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system.

Redila VA, Chavkin C.

Psychopharmacology (Berl). 2008 Sep;200(1):59-70. doi: 10.1007/s00213-008-1122-y. Epub 2008 Jun 25.

Supplemental Content

Loading ...
Support Center